← Back to Search

Neurotoxin

Botulinum Toxin A for Facial Flushing

N/A
Waitlist Available
Led By Murad Alam, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 8 weeks

Summary

This trial will test the use of botulinum toxin A to see if it can help reduce facial flushing.

Who is the study for?
This trial is for adults aged 18-65 who experience persistent facial flushing and can give informed consent. It's not suitable for those with certain medical conditions like heart failure, bleeding disorders, or allergies to botox ingredients. Pregnant women, people on specific medications, or those who've had recent cosmetic treatments in the face are excluded.
What is being tested?
The study is testing whether botulinum toxin A (Botox®) injections can help treat facial flushing compared to a saline control. This pilot study aims to assess the feasibility of using Botox for this purpose.
What are the potential side effects?
Potential side effects may include localized pain at injection sites, muscle weakness near treated areas, headache, allergic reactions such as itching or rash, and flu-like symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Spectrophotometer measurement

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: botulinum toxin AExperimental Treatment1 Intervention
This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
Group II: Saline ControlPlacebo Group1 Intervention
This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
botulinum toxin A
2010
Completed Phase 4
~410

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,649 Previous Clinical Trials
958,755 Total Patients Enrolled
Murad Alam, MDPrincipal InvestigatorNorthwestern University
69 Previous Clinical Trials
2,564 Total Patients Enrolled

Media Library

Botulinum Toxin A (Neurotoxin) Clinical Trial Eligibility Overview. Trial Name: NCT02216838 — N/A
Facial Flushing Research Study Groups: botulinum toxin A, Saline Control
Facial Flushing Clinical Trial 2023: Botulinum Toxin A Highlights & Side Effects. Trial Name: NCT02216838 — N/A
Botulinum Toxin A (Neurotoxin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02216838 — N/A
~1 spots leftby Dec 2025